I am a final-year medical student studying pediatrics, and I am aiming to master the subject in-depth to not only pass my exams but to become a well-rounded and knowledgeable physician. Please help me by explaining the following topics/concepts in detail: Conceptual Clarity: Provide a thorough explanation of the underlying pathophysiology, clinical features, diagnostic approach, and treatment guidelines based on the latest evidence and protocols from standard textbooks such as williams, Harriet Lane Handbook, Tintinalli’s Emergency Medicine, and the American Academy of Pediatrics (AAP) guidelines. Be sure to include why certain steps are taken in diagnosis and treatment. Evidence-Based Practices: For each topic, include evidence-based recommendations and reference current clinical protocols, such as those from UpToDate, PubMed, or specific clinical practice guidelines (e.g., figo acog, WHO). Practical Applications: Highlight how the concepts apply in real-world clinical scenarios. For example, explain what signs and symptoms to look for in the clinical setting, when to suspect certain conditions, and what practical steps to take in diagnosis, management, and follow-up care. Clinical Reasoning: When discussing each condition, explain the clinical reasoning process. Break down why one diagnosis is more likely than others based on the presenting signs and symptoms and what investigations would be required. Differential Diagnosis and Red Flags: For each condition, list important differential diagnoses and red flags that should not be missed. Patient-Centered Care: Discuss how to approach patient care in obgyn in a holistic manner, including family involvement, ethical considerations, and the psychological impact of illness on children and their families. Long-Term Follow-Up: Emphasize any conditions in pediatrics that require long-term follow-up or have chronic implications, including how to manage these over time. For each topic, ensure to include: Diagnostic criteria or features Management steps (pharmacological and non-pharmacological) Complications and how to prevent/manage them Prognosis and expected outcomes. First topic is sti. Since topic is long present three subtopic at atime.
Reading File
Finding Sources
Finding Sources
Finding Sources
Searching PubMed
sexually transmitted infections children adolescents management
Reading File
Reading File
Finding Sources
Finding Sources
Searching PubMed
gonorrhea chlamydia adolescents treatment CDC guidelines
Reading File
Reading File
Reading File
Searching PubMed
congenital syphilis diagnosis treatment neonates guidelines
Reading File
Reading File
Finding Sources
Searching the Web
CDC 2021 STI treatment guidelines pediatric gonorrhea chlamydia syphilis children
I now have comprehensive information from multiple authoritative sources. Let me compile the definitive, detailed response.
Sexually Transmitted Infections (STIs) in Pediatrics
Part 1: Gonorrhea · Chlamydia · Syphilis
Sources: Red Book 2021 (AAP), Rosen's Emergency Medicine, Washington Manual, Creasy & Resnik's Maternal-Fetal Medicine, CDC STI Treatment Guidelines 2021, Fitzpatrick's Dermatology, Harrison's Principles of Internal Medicine
Foundational Concept: STIs in Children — A Critical Safeguarding Principle
Before addressing individual pathogens, this principle from the Red Book (AAP) must be internalized:
"Although an STI in an infant or child early in life can be the result of vertical transmission, nonabusive horizontal transmission, or autoinoculation, STIs such as gonorrhea, syphilis, chlamydia, genital herpes, HIV, trichomoniasis, or anogenital warts should raise strong suspicion of sexual abuse if acquired after the neonatal period."
Clinical reasoning key: When you encounter an STI in a prepubertal child, your default must be to consider and rule out sexual abuse. Appropriate social services and law enforcement agencies must be involved. A child abuse pediatrician consultation should be sought where available. All 50 US states mandate reporting of suspected child abuse.
🔴 SUBTOPIC 1: GONORRHEA IN PEDIATRICS
Pathogen & Pathophysiology
Neisseria gonorrhoeae — Gram-negative intracellular diplococcus. Humans are the only reservoir. Transmission is almost exclusively sexual. The incubation period is 3–7 days. Pathogenesis begins with pilus-mediated adherence to mucosal epithelium → endocytosis → intracellular replication → local inflammation → ascent to upper tract structures.
Why is it dangerous in children?
- In neonates, vertical transmission during delivery causes ophthalmia neonatorum — a potentially blinding condition
- In prepubertal girls, the vaginal epithelium (non-estrogenized, thin) is highly susceptible to gonococcal vaginitis (unlike adult women who develop cervicitis)
- In any child beyond the neonatal period, gonococcal infection strongly implies sexual abuse
Clinical Features by Age Group
1. Neonates (Ophthalmia Neonatorum)
- Onset: 2–5 days after birth (distinguishes from chlamydial conjunctivitis, which appears at 5–14 days)
- Bilateral purulent conjunctivitis — copious, hyperacute discharge
- Corneal ulceration and perforation can occur within 24 hours if untreated → blindness
- Systemic spread: septicemia, arthritis, meningitis in untreated cases
2. Prepubertal Children
- Girls: Vulvovaginitis (not cervicitis, because pre-estrogenic vaginal epithelium is thin and columnar cells are susceptible). Presents with purulent vaginal discharge, dysuria, vulvar erythema/edema
- Boys: Urethral discharge, dysuria
- Both sexes: Pharyngitis (usually asymptomatic, from oral contact), rectal infection (from anal contact — often asymptomatic or with discharge/tenesmus)
3. Adolescents (Similar to Adults)
- Males: Urethritis — copious purulent urethral discharge + dysuria (symptomatic within 1–2 weeks)
- Females: Cervicitis — often asymptomatic until ascending infection; when symptomatic: abnormal vaginal discharge, dyspareunia, intermenstrual bleeding
- Pharyngitis: Usually asymptomatic; may mimic viral/bacterial pharyngitis
- Disseminated Gonococcal Infection (DGI): Triad of dermatitis (petechiae/pustules on extremities), tenosynovitis, and migratory polyarthritis — occurs in ~1–3% of untreated infections
- PID in adolescent girls: Most serious complication — fever, lower abdominal pain, cervical motion tenderness
Diagnostic Approach
Clinical Reasoning
The clinical presentation alone cannot reliably differentiate gonorrhea from chlamydia. Both frequently co-infect the same patient. Always test for both simultaneously.
| Test | Use Case |
|---|---|
| NAAT (Nucleic Acid Amplification Test) | Gold standard; sensitivity >95%, specificity ~99%; first-line for all adolescents and for legal purposes in abuse cases |
| Culture on Thayer-Martin medium | Preferred in prepubertal children (medicolegal evidence); allows antimicrobial sensitivity testing |
| Gram stain (urethral discharge) | Gram-negative intracellular diplococci in PMNs — rapid, useful in males; less sensitive in females |
Specimen sites in sexual abuse evaluation (AAP Red Book):
- Prepubertal: Culture or NAAT from pharynx, anus, vagina (girls), urine (boys)
- Postpubertal: NAAT from all sites of penetration/attempted penetration
Why culture in prepubertal children? NAAT is preferred diagnostically but culture remains important for legal cases — it provides isolates for antibiogram and is defensible in court. Some AAP guidance recommends both NAAT + culture in abuse cases.
Additional workup: Co-test for chlamydia, syphilis, HIV, hepatitis B. In DGI: blood cultures, joint fluid Gram stain/culture.
Treatment (CDC 2021 + AAP Guidelines)
Neonates — Ophthalmia Neonatorum
| Regimen | Details |
|---|---|
| Ceftriaxone 25–50 mg/kg IV/IM (max 125–250 mg) | Single dose |
| Eye irrigation with normal saline | Adjunct — remove discharge |
| Topical antibiotics alone not sufficient | |
| Admission advised | Monitor for systemic spread |
Prophylaxis at birth: Erythromycin 0.5% ophthalmic ointment to both eyes within 1 hour of birth (universal in US) — prevents gonococcal ophthalmia neonatorum. Note: Does not reliably prevent chlamydial conjunctivitis.
Prepubertal Children (Non-neonatal)
| Condition | Regimen |
|---|---|
| Gonococcal vulvovaginitis/urethritis (child ≥45 kg) | Ceftriaxone 500 mg IM × 1 |
| Gonococcal vulvovaginitis/urethritis (child <45 kg) | Ceftriaxone 25–50 mg/kg IM × 1 (max 250 mg) |
| Pharyngeal/rectal gonorrhea | Ceftriaxone (same dosing) |
| If chlamydia co-infection not ruled out | Add azithromycin 20 mg/kg PO × 1 (max 1 g) — avoid doxycycline in children <8 years |
Adolescents (Adult Dosing)
| Condition | Regimen |
|---|---|
| Uncomplicated urogenital/rectal/pharyngeal | Ceftriaxone 500 mg IM × 1 (1 g if ≥150 kg) |
| + Chlamydia not ruled out | + Doxycycline 100 mg PO BID × 7 days |
| Penicillin/cephalosporin allergy | Gentamicin 240 mg IM + Azithromycin 2 g PO × 1 |
| Disseminated Gonococcal Infection | Ceftriaxone 1 g IV/IM daily; switch to oral after 24–48 h of improvement; total ≥7 days |
| PID (outpatient) | Ceftriaxone 500 mg IM × 1 + Doxycycline 100 mg BID × 14 days + Metronidazole 500 mg BID × 14 days |
| PID (inpatient) | Ceftriaxone 1 g IV or Cefoxitin 2 g IV q6h + Doxycycline + Metronidazole |
Why ceftriaxone? Fluoroquinolone resistance is now widespread (CDC no longer recommends fluoroquinolones for gonorrhea). Ceftriaxone remains highly effective due to its activity against penicillinase-producing and PPNG strains.
Complications
| Complication | Details |
|---|---|
| Ophthalmia neonatorum → blindness | If untreated within hours |
| PID → infertility, ectopic pregnancy, chronic pelvic pain | 10–15% of untreated females develop PID |
| Disseminated Gonococcal Infection (DGI) | Dermatitis-arthritis syndrome |
| Gonococcal meningitis/endocarditis | Rare but life-threatening |
| Neonatal sepsis | If DGI occurs in neonate |
| Psychological trauma (if abuse-related) | Requires multidisciplinary support |
Differential Diagnosis & Red Flags
| Differential | Distinguishing Feature |
|---|---|
| Chlamydial urethritis/cervicitis | Scant mucoid discharge (vs. purulent); more indolent |
| Bacterial vaginosis | Clue cells on wet mount; fishy odor; no inflammation |
| Trichomoniasis | Frothy green discharge; motile trichomonads on wet mount |
| Nonspecific vulvovaginitis | No pathogen; related to hygiene/foreign body |
| 🚩 RED FLAG: Gonococcal infection in a prepubertal child | Mandatory child abuse investigation |
| 🚩 Neonatal conjunctivitis Day 1–4 | Always consider gonorrhea; emergency ophthalmology referral |
| 🚩 DGI with petechiae in adolescent | Do not confuse with meningococcemia — blood cultures critical |
Prognosis & Long-Term Follow-Up
- Single-dose ceftriaxone is curative in >99% of susceptible cases
- Test-of-cure not routinely needed unless pharyngeal site or symptoms persist; but retest at 3 months due to high reinfection rate
- Partner treatment is mandatory — expedited partner therapy (EPT) where legally permitted
- PID: Long-term sequelae (infertility, ectopic pregnancy, chronic pain) risk increases with each PID episode — emphasize prevention
- Abuse cases: Long-term psychological follow-up, child protective services involvement
🟠 SUBTOPIC 2: CHLAMYDIA IN PEDIATRICS
Pathogen & Pathophysiology
Chlamydia trachomatis — obligate intracellular organism. Two distinct clinical forms in pediatrics:
- Perinatal (serovars D-K): Neonatal conjunctivitis, neonatal pneumonia, genital infections
- Lymphogranuloma Venereum (serovars L1, L2, L3): Destructive lymphadenopathy
Lifecycle: Elementary bodies (EB — infectious, metabolically inactive) attach to host cells → transform to reticulate bodies (RB — metabolically active, replicating) → lysosomal escape → burst cell, release new EBs. This intracellular life cycle explains why beta-lactams are ineffective (cell wall–active antibiotics cannot penetrate) — macrolides, azithromycin, and tetracyclines are required.
It is the most commonly reported STI in the United States (~1.7 million cases/year). Approximately 50% of men and 70% of women are asymptomatic — making screening essential.
Clinical Features by Age Group
1. Neonates (Acquired during vaginal delivery from infected mother)
- Acquisition rate: ~50% of vaginally born infants from infected mothers; some even after C-section with intact membranes
- Neonatal Chlamydial Conjunctivitis (Inclusion Conjunctivitis)
- Onset: 5–14 days after birth (vs. 2–5 days for gonorrhea — key distinction)
- Bilateral mucopurulent discharge; eyelid edema; NOT blinding (unlike gonorrhea)
- Self-limiting but treated to prevent chronic trachoma-like changes
- Neonatal Chlamydial Pneumonia
- Onset: 3–19 weeks of age
- Classic presentation: Afebrile (or low-grade fever), staccato cough ("repetitive paroxysmal cough without whoop"), tachypnea, eosinophilia on CBC, bilateral interstitial infiltrates on CXR
- Rhinitis (snuffles) may precede respiratory symptoms
- Hyperinflation on X-ray; arterial blood gas may show hypoxia
- Diagnosis: NAAT preferred; DFA (direct fluorescent antibody), culture from nasopharyngeal aspirate
2. Prepubertal Children (Beyond Neonatal Period)
- Genital chlamydia infection in a prepubertal child strongly suggests sexual abuse
- Girls: Vulvovaginitis with mucopurulent vaginal discharge (less florid than gonorrhea)
- Boys: Urethral discharge, dysuria
- Rectal and pharyngeal infections possible (usually asymptomatic)
- Exception: Perinatally acquired chlamydia can persist in the vagina/rectum for up to 2–3 years — this must be considered before labeling as abuse in very young toddlers
3. Adolescents
- Most common STI in adolescents 15–24 years old
- Urethritis (males): Scant, mucoid, less purulent discharge; less dysuria than gonorrhea; delayed presentation
- Cervicitis (females): Mucopurulent cervical discharge or postcoital bleeding — often asymptomatic ("silent cervicitis")
- Ascending infection:
- Epididymitis/Orchitis: Unilateral scrotal pain + swelling; more common with chlamydia than gonorrhea alone
- PID: Chlamydia is the leading cause of PID — often indolent or silent; leads to Fitz-Hugh–Curtis syndrome (perihepatitis — right upper quadrant pain)
- Reactive Arthritis (formerly Reiter's): Urethritis + conjunctivitis + arthritis — HLA-B27 associated
- LGV (serovars L1–L3): Painful inguinal lymphadenopathy (buboes) → systemic illness; primarily in MSM
Diagnostic Approach
| Test | Notes |
|---|---|
| NAAT (first-line) | Sensitivity >90%, specificity 99%; vaginal, endocervical, urethral, urine, rectal, pharyngeal specimens |
| Culture | Required in medicolegal (child abuse) settings; uses McCoy cell culture |
| DFA (Direct Fluorescent Antibody) | Useful for neonatal conjunctivitis (conjunctival scrapings — not swab) |
| IgM serology | For neonatal pneumonia (C. trachomatis IgM ≥1:32 supportive but not definitive) |
Clinical reasoning for neonatal pneumonia diagnosis: Bilateral diffuse interstitial infiltrates + staccato cough + eosinophilia + age 3–19 weeks + history of maternal STI = Chlamydial pneumonia until proven otherwise. Confirm with NAAT from nasopharyngeal aspirate.
Screening recommendations (AAP/CDC):
- Annual NAAT screening for all sexually active females ≤25 years
- Screening in males if in high-prevalence settings (e.g., correctional facilities, STI clinics)
- Screen during pregnancy (first prenatal visit, repeat at 36 weeks if high-risk)
Treatment
Neonatal Conjunctivitis
| Regimen | Details |
|---|---|
| Erythromycin 50 mg/kg/day PO in 4 divided doses × 14 days | First-line |
| Azithromycin 20 mg/kg/day PO × 3 days | Alternative |
| Topical antibiotics alone — INSUFFICIENT | Do not treat neonatal chlamydial conjunctivitis with eye drops alone |
| Screen and treat the mother and her partner | Critical |
⚠️ Pyloric stenosis warning: Erythromycin in neonates < 6 weeks is associated with infantile hypertrophic pyloric stenosis (IHPS). Inform parents; monitor for projectile vomiting. Azithromycin may be preferred in some centers, though CDC currently lists erythromycin as first-line.
Neonatal Pneumonia
- Erythromycin 50 mg/kg/day PO × 14 days — same as conjunctivitis
- Hospitalization if hypoxic or severe respiratory compromise
- Efficacy is ~80% — may require a second course
Prepubertal Children (Genital Infection)
| Weight | Regimen |
|---|---|
| <45 kg | Erythromycin 50 mg/kg/day PO divided QID × 14 days |
| ≥45 kg, age <8 years | Azithromycin 1 g PO × 1 |
| ≥45 kg, age ≥8 years | Azithromycin 1 g PO × 1 OR Doxycycline 100 mg PO BID × 7 days |
Why avoid doxycycline in children <8 years? Tetracyclines bind calcium → deposit in developing teeth (permanent discoloration/"tetracycline teeth") and bones. This is the reason azithromycin or erythromycin is used in younger children.
Adolescents
| Condition | Regimen |
|---|---|
| Uncomplicated urethritis/cervicitis/proctitis | Doxycycline 100 mg PO BID × 7 days (preferred — superior efficacy in rectal infections over azithromycin) |
| Alternative | Azithromycin 1 g PO × 1 (less efficacious in rectal infections) |
| Alternative | Levofloxacin 500 mg PO daily × 7 days |
| Chlamydial PID | Doxycycline 100 mg BID + Ceftriaxone 500 mg IM × 1 + Metronidazole 500 mg BID × 14 days |
| During pregnancy | Azithromycin 1 g PO × 1 (doxycycline contraindicated in pregnancy) |
| Neonatal/infant treatment | Erythromycin (as above) |
Complications
| Complication | Details |
|---|---|
| PID → Tubal factor infertility | Silent PID is particularly treacherous in adolescents |
| Ectopic pregnancy | Tubal scarring from repeated PID |
| Chronic pelvic pain | Peritubal adhesions |
| Fitz-Hugh–Curtis syndrome | Perihepatitis — RUQ pain mimicking cholecystitis |
| Reactive arthritis | HLA-B27 associated |
| Neonatal conjunctivitis → pannus (corneal vascularization) | If untreated |
| Neonatal pneumonia | Can be severe; rare deaths reported |
| LGV → rectal stricture | Late complication of untreated LGV proctocolitis |
Differential Diagnosis & Red Flags
| Differential | Distinguishing Feature |
|---|---|
| Gonorrhea | More purulent discharge; earlier onset in neonates (2–5 days vs. 5–14 days); NAAT differentiates |
| RSV/Viral bronchiolitis | Wheeze more prominent; no staccato cough; no eosinophilia; seasonal clustering |
| Pertussis | Whooping cough; different bacterial culture; PCR differentiates |
| PID from other organisms | Mixed flora; clinical features overlap — treat empirically for both |
| 🚩 Genital chlamydia in prepubertal child after infancy | Child abuse evaluation mandatory |
| 🚩 Afebrile pneumonia 3–19 weeks with eosinophilia | Think chlamydial pneumonia — do not dismiss as viral |
| 🚩 Neonatal conjunctivitis — don't assume chemical | Chemical conjunctivitis from eye prophylaxis resolves in 24–36 h; infectious forms persist |
Prognosis & Long-Term Follow-Up
- Test-of-cure: Not recommended for uncomplicated urogenital chlamydia (NAAT may remain positive for 3 weeks post-treatment due to dead nucleic acids)
- Retest at 3 months — high reinfection rate (main reason for continued spread)
- Neonatal pneumonia: Generally good prognosis with treatment; some children develop recurrent wheezing/asthma in later childhood
- Fertility counseling for adolescent girls with PID history
- Partner notification and treatment essential
🟡 SUBTOPIC 3: SYPHILIS IN PEDIATRICS
Pathogen & Pathophysiology
Treponema pallidum — motile spirochete; cannot be cultured on artificial media. It eludes host immunity by:
- Minimal surface proteins (sparse lipoproteins → limited antigenic targets)
- Mimicking host cell membranes with host-derived phospholipids
- Slow replication (doubling time ~30 hours)
Routes of transmission in pediatrics:
- Vertical (most common in children): Transplacental or intrapartum → congenital syphilis
- Sexual abuse: Beyond neonatal period — acquired syphilis in a child mandates abuse investigation
- Adolescent sexual activity: Increasing rates, especially in MSM
T. pallidum crosses the placenta as early as 6 gestational weeks, but fetal damage does not occur until >16 weeks (when fetal immunocompetence develops). This is why early treatment during pregnancy can prevent congenital syphilis even if acquired in the first trimester.
Congenital Syphilis — The Core Pediatric Entity
Maternal Risk Factors
- Untreated or inadequately treated maternal syphilis
- Primary/secondary stage maternal infection (highest spirochetemia → highest transmission risk ~70–100%)
- Latent syphilis (transmission still occurs ~30%)
- Inadequate antenatal care
Classification (CDC Case Definition)
Confirmed: T. pallidum identified by darkfield microscopy or fluorescent antibody in lesions, placenta, or autopsy material
Presumptive:
- Any infant whose mother had untreated or inadequately treated syphilis at delivery, OR
- Any infant with reactive treponemal test AND any of: physical exam findings, reactive CSF VDRL, elevated CSF WBC/protein, positive 19S-IgM FTA-ABS
Clinical Features: Early vs. Late Congenital Syphilis
Early Congenital Syphilis (Onset < 2 Years)
~2/3 of infected infants are asymptomatic at birth — symptoms appear at 3–8 weeks of life.
| Feature | Description |
|---|---|
| Snuffles | Serosanguineous nasal discharge ("bloody snot") — highly infectious; do not confuse with common cold |
| Maculopapular rash | Progresses to desquamation, vesicles, bullae (especially palms, soles) |
| Pemphigus syphiliticus | Bullous lesions on palms/soles — pathognomonic in neonates |
| Hepatosplenomegaly | Extremely common; jaundice, elevated LFTs |
| Lymphadenopathy | Generalized |
| Osteochondritis (Parrot pseudoparalysis) | Painful, syphilitic osteochondritis → infant refuses to move limb; resembles paralysis |
| Periostitis | Symmetric long-bone involvement on X-ray — "celery-stalk" metaphyseal lucency |
| Chorioretinitis, iritis | Ophthalmic involvement → potential blindness |
| Anemia, thrombocytopenia | Hemolytic anemia; thrombocytopenic purpura |
| CNS involvement | Aseptic meningitis, bulging fontanelle (in ~5%) |
| Hydrops fetalis | Severe fetal infection — non-immune hydrops |
Late Congenital Syphilis (Onset ≥ 2 Years — Stigmata of Scarring)
These are irreversible manifestations from untreated early disease — result of scarring and chronic inflammation:
| Manifestation | Notes |
|---|---|
| Hutchinson teeth | Notched, barrel-shaped permanent upper central incisors — pathognomonic |
| Mulberry molars | Multiple poorly developed cusps — Moon's molars |
| Interstitial keratitis | Corneal vascularization → blindness (8th–10th year); most common cause of late manifestation |
| 8th nerve deafness | Sensorineural hearing loss — bilateral; may be progressive |
| Saddle-nose deformity | Nasal bridge collapse from periostitis |
| Saber shins | Anterior tibial bowing from periostitis |
| Rhagades | Perioral fissures (linear scars around mouth/nose) |
| Clutton joints | Bilateral painless joint effusions (knees, elbows) — hydrarthrosis |
| Neurosyphilis | Mental retardation, hydrocephalus, general paresis, optic nerve atrophy |
Hutchinson's triad (classic): Interstitial keratitis + 8th nerve deafness + Hutchinson teeth — confirms late congenital syphilis
Acquired Syphilis in Adolescents (Stages)
| Stage | Features |
|---|---|
| Primary | Single painless chancre at site of inoculation (genitals, anus, mouth, lips) + regional lymphadenopathy; heals spontaneously in 3–6 weeks |
| Secondary | Diffuse maculopapular rash including palms and soles (pathognomonic feature); condylomata lata (flat warty lesions around genitals/anus); mucous patches; flu-like illness; highly infectious |
| Latent | Asymptomatic; reactive serology; early latent (<1 year), late latent (≥1 year) |
| Tertiary | Gummas, cardiovascular syphilis, neurosyphilis — rare in adolescents |
| Neurosyphilis | Any stage; meningitis, cranial nerve palsies, Argyll Robertson pupil (accommodates but doesn't react to light) |
Diagnostic Approach
Neonates/Congenital Syphilis
| Test | Notes |
|---|---|
| Maternal RPR/VDRL (nontreponemal) | Screen in all pregnant women (1st trimester + 28 weeks + delivery in high-risk areas) |
| Infant serum RPR or VDRL | Compare with maternal titer — infant titer >4× maternal titer is significant |
| Darkfield microscopy of lesions/snuffles discharge | Direct visualization — gold standard for active lesions |
| Treponemal test (FTA-ABS, TP-PA, TPHA) | Confirms T. pallidum exposure — but passively transferred maternal IgG can remain positive up to 18 months in uninfected infants |
| Infant IgM FTA-ABS (19S fraction) | Cannot be passively transferred — if positive, indicates active infant infection |
| LP for CSF VDRL | Indicated in presumptive congenital syphilis — reactive CSF VDRL = neurosyphilis |
| Long bone X-rays | Periostitis, metaphyseal lucencies ("celery-stalk"), osteochondritis |
| CBC, LFTs, ophthalmology, audiology | Assess systemic involvement |
| Placental pathology | Large edematous placenta + villitis = syphilitic placentitis |
Adolescents (Acquired Syphilis)
| Screening | Confirmatory |
|---|---|
| RPR or VDRL (nontreponemal — titer reflects disease activity) | FTA-ABS or TP-PA (treponemal — remains positive for life) |
| False-positive RPR: Pregnancy, autoimmune disease, viral infections | Treponemal test resolves false positives |
"Reactive serology + clinical features = treat" — do not wait for darkfield microscopy results.
Treatment (CDC 2021 + AAP Red Book)
Key principle: Penicillin is the ONLY proven treatment for all stages of syphilis — no proven alternatives for congenital syphilis or neurosyphilis.
Congenital Syphilis
| Scenario | Regimen |
|---|---|
| Confirmed/probable congenital syphilis | Aqueous crystalline penicillin G 50,000 units/kg IV q12h (age ≤7 days) or q8h (age >7 days) × 10 days, OR Procaine penicillin G 50,000 units/kg IM × 10 days |
| Less-likely congenital syphilis (adequately treated mother, normal exam/labs) | Benzathine penicillin G 50,000 units/kg IM × 1 dose |
| Penicillin allergy | Desensitize and give penicillin — no alternative is proven |
Why IV aqueous penicillin for confirmed cases? It achieves treponemicidal levels in the CSF (neurosyphilis coverage) — benzathine penicillin does NOT penetrate CSF adequately.
Acquired Syphilis in Adolescents
| Stage | Regimen |
|---|---|
| Primary/Secondary/Early Latent | Benzathine penicillin G 2.4 million units IM × 1 |
| Late Latent/Latent of Unknown Duration | Benzathine penicillin G 2.4 million units IM weekly × 3 doses |
| Neurosyphilis | Aqueous crystalline penicillin G 18–24 million units/day IV (3–4 million units IV q4h) × 10–14 days |
| Penicillin allergy (non-pregnant) | Doxycycline 100 mg PO BID × 14 days (primary/secondary) or 28 days (latent) |
| Pregnancy + penicillin allergy | Desensitize and treat with penicillin — no alternative acceptable |
Jarisch-Herxheimer Reaction: Fever, rigors, myalgias, headache within 2–8 hours of first penicillin dose — caused by rapid lysis of spirochetes → cytokine release. Manage with antipyretics; do not stop treatment. Important to warn patient/parents.
Maternal Treatment to Prevent Congenital Syphilis
- Treat maternal syphilis ≥30 days before delivery for full protection
- Treatment in the last trimester still reduces, but does not eliminate, neonatal infection risk (Systematic Review, PMID: 41671009)
- Monthly RPR titers post-treatment to confirm adequate response
Complications
| Complication | Notes |
|---|---|
| Stillbirth, miscarriage | Most severe fetal outcomes with primary/secondary syphilis |
| Hydrops fetalis | Non-immune; fetal anemia, cardiac failure |
| Congenital blindness | Chorioretinitis, interstitial keratitis |
| Sensorineural deafness | 8th nerve — may be progressive |
| Neurodevelopmental delay | From CNS involvement |
| Jarisch-Herxheimer | Especially dangerous in pregnancy (fetal distress) |
| Cardiovascular syphilis | Aortitis, aortic regurgitation — in untreated adults |
Differential Diagnosis & Red Flags
| Differential | Distinguishing Feature |
|---|---|
| TORCH infections | CMV, toxoplasma, rubella — hepatosplenomegaly, jaundice — serology differentiates |
| Sepsis (neonatal) | Snuffles + rash + HSM + thrombocytopenia — RPR/VDRL differentiates |
| Hemolytic disease of newborn | Coombs test positive; no rash; no skeletal changes |
| Secondary syphilis rash | Psoriasis, pityriasis rosea, drug eruption — serology differentiates |
| Epiphyseal trauma | Parrot pseudoparalysis — skeletal survey + serology |
| 🚩 Rash on palms + soles in any patient | ALWAYS test for syphilis |
| 🚩 Hutchinson teeth + deafness + keratitis | Congenital syphilis — late — requires LP and full workup |
| 🚩 Painless genital ulcer in adolescent | Primary syphilis — do NOT dismiss as "trauma" |
| 🚩 Rising syphilis rates in adolescents/MSM | Especially if HIV co-infection — more aggressive surveillance needed |
Prognosis & Long-Term Follow-Up
Congenital Syphilis:
- With early adequate treatment: Good prognosis — most sequelae preventable if treated before 3 months
- Late stigmata (Hutchinson teeth, saber shins, saddle nose) are irreversible — cosmetic and rehabilitative management
- 8th nerve deafness: May respond to penicillin if caught early; progressive if late
- Interstitial keratitis: Often develops 5–15 years after birth — annual ophthalmology follow-up until adulthood
- Audiology follow-up at regular intervals
- Neuropsychological assessment for CNS involvement
Acquired Syphilis:
- Post-treatment RPR titers should decline 4-fold by 6–12 months (primary/secondary) or 12–24 months (latent) — failure to decline suggests treatment failure, reinfection, or neurosyphilis
- Lumbar puncture if neurological symptoms develop or titers fail to decline
- HIV testing essential — syphilis dramatically increases HIV transmission/acquisition risk
Summary Table: Key Distinctions
| Feature | Gonorrhea | Chlamydia | Syphilis |
|---|---|---|---|
| Organism | N. gonorrhoeae (Gram-neg diplococcus) | C. trachomatis (obligate intracellular) | T. pallidum (spirochete) |
| Neonatal presentation | Ophthalmia (Day 2–5), copious purulent | Conjunctivitis (Day 5–14), pneumonia (3–19 wk) | Snuffles, rash, HSM, pseudoparalysis |
| Diagnosis gold standard | NAAT (culture in abuse cases) | NAAT | Serology (RPR + FTA-ABS) + darkfield |
| Treatment in neonates | Ceftriaxone IV/IM | Erythromycin PO × 14 days | Aqueous penicillin G IV × 10 days |
| Treatment in adolescents | Ceftriaxone 500 mg IM × 1 | Doxycycline 100 mg BID × 7 days | Benzathine PCN G 2.4 MU IM × 1 |
| Child abuse implication | Strong suspicion if prepubertal | Strong suspicion if >2–3 years and prepubertal | Strong suspicion beyond neonatal period |
| Key complication | PID, blindness, DGI | Silent PID, infertility, Fitz-Hugh–Curtis | Congenital stigmata, neurosyphilis |
Patient-Centered & Ethical Considerations
- Confidentiality: All 50 US states allow minors to consent to STI testing and treatment without parental consent — respect this; it reduces barriers to care
- Non-judgmental approach: Adolescents with STIs require non-stigmatizing care. Shame prevents re-testing and partner notification
- Mandatory reporting: STIs in children implying sexual abuse are mandatory reports to child protective services
- Family communication: When STI is abuse-related, involve child life specialists, social workers, and child advocacy centers in communication
- Psychological support: Children who have experienced sexual abuse need long-term mental health follow-up (PTSD, depression, behavioral disorders)
- Cultural sensitivity: Discuss sexual health in age-appropriate, culturally sensitive language; involve interpreters as needed
- Expedited Partner Therapy (EPT): Legal in most US states — give prescriptions/medications to the patient to deliver to partners — reduces reinfection rates by ~50%
When you're ready, I'll continue with the next three STI subtopics: HIV in pediatrics, HPV, and Trichomonas/HSV/other STIs — or we can proceed to another topic entirely. Just let me know.
This is a shared conversation. Sign in to Orris to start your own chat.